title: Intensive statin therapy for Chinese patients with coronary artery disease undergoing percutaneous coronary intervention (ISCAP study): rationale and design.
abstract: BACKGROUND
  Myocardial necrosis is related to higher incidence of cardiovascular events and higher mortality rates during follow-up. Statins have been demonstrated to lower the risk of periprocedural myocardial infarction. The aim of this study is to evaluate the safety and efficacy of intensive statin therapy and the long-term outcome of patients in the Asian population.
  
  
  METHODS
  Approximately 1,100 patients with stable angina or non-ST elevation acute coronary syndrome undergoing selective percutaneous coronary intervention (PCI) are enrolled in this study. Patients are randomized either to the experimental group (80 mg atorvastatin 80 mg/day × 2 days before and 40 mg/day × 30 days after PCI) or to the control group (usual care). Creatine kinase-MB (CK-MB), troponin I (cTnI), and serum creatine are measured at 24 hours after the procedure. The total follow-up period is 6 months. The primary objective is to evaluate the efficacy of intensive atorvastatin treatment compared with usual care in reducing 30-day primary cardiovascular endpoints in patients undergoing selective PCI. Secondary endpoints are changes in myocardial biomarkers (cTnI, CK-MB) and hs-CRP, CIN morbidity, 6-month clinical outcomes, and safety.
  
  
  CONCLUSIONS
  The result of the ISCAP study will provide important evidence on the efficacy and safety of periprocedural serial intensive statin treatment in Asian patients with coronary artery disease undergoing selective PCI.
authors.affiliation: Department of Cardiology, Peking University First Hospital, Beijing, China.
authors.forename: Peng
authors.initials: P
authors.lastname: Liu
authors.forename: Jie
authors.initials: J
authors.lastname: Jiang
authors.forename: Jianping
authors.initials: J
authors.lastname: Li
authors.forename: Tao
authors.initials: T
authors.lastname: Hong
authors.forename: Yan
authors.initials: Y
authors.lastname: Zhang
authors.forename: Ronghui
authors.initials: R
authors.lastname: Yu
authors.forename: Jia
authors.initials: J
authors.lastname: Jia
authors.forename: Yong
authors.initials: Y
authors.lastname: Huo
mesh_terms: D015906:Angioplasty, Balloon, Coronary / Q000009:adverse effects / Q000401:mortality; D044466:Asian People; D000069059:Atorvastatin; D015415:Biomarkers / Q000097:blood; D002097:C-Reactive Protein / Q000378:metabolism; D002318:Cardiovascular Diseases / Q000097:blood / Q000209:etiology / Q000401:mortality / Q000517:prevention & control*; D002681:China / Q000453:epidemiology; D003324:Coronary Artery Disease / Q000188:drug therapy / Q000208:ethnology / Q000401:mortality / Q000628:therapy*; D003401:Creatine / Q000097:blood; D052279:Creatine Kinase, MB Form / Q000097:blood; D004334:Drug Administration Schedule; D006538:Heptanoic Acids / Q000008:administration & dosage* / Q000009:adverse effects; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000008:administration & dosage* / Q000009:adverse effects; D011758:Pyrroles / Q000008:administration & dosage* / Q000009:adverse effects; D012107:Research Design; D013997:Time Factors; D016896:Treatment Outcome; D019210:Troponin I / Q000097:blood
chemical_list: D015415:Biomarkers; D006538:Heptanoic Acids; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D011758:Pyrroles; D019210:Troponin I; D002097:C-Reactive Protein; D000069059:Atorvastatin; D052279:Creatine Kinase, MB Form; D003401:Creatine